Moreover, diabetic guidelines such as American Diabetes Association (ADA) guidelines are suggesting new diabetic treatments such as sodium-glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide 1 receptor agonists (GLP-1a) as glucose-lowering agents for those with established CVD or multiple risk factors as both have been proven to decrease the risk of major cardiovascular events including myocardial infarction, stroke, and cardiovascular death [13]. The gene discussed is GLP1R; the disease is diabetes mellitus.